In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis

被引：40

作者：

Chen, YH

Garber, E

Zhao, QQ

Ge, YG

Wikler, MA

Kaniga, K

Saiman, L

机构：

[1] Columbia Univ, Dept Pediat, New York, NY 10032 USA

[2] Peninsula Pharmaceut Inc, Alameda, CA USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2005年 / 49卷 / 06期

关键词：

D O I：

10.1128/AAC.49.6.2510-2511.2005

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Doripenem 50% inhibitory concentrations (MIC50) and 90% inhibitory concentrations (MIC90) for multidrug-resistant strains of mucoid Pseudomonas aeruginosa (n = 200 strains), nonmucoid P. aeruginosa (n = 200), and Burkholdetia cepacia complex (n = 200) isolated from patients with cystic fibrosis were 8 and 32, 8 and 64, and 8 and 32 mu g/ml, respectively. Doripenem had somewhat better activity than established antimicrobial agents.

引用

页码：2510 / 2511

页数：2

共 11 条

[1] BLUMER J, IN PRESS CHEST
[2] In vitro antimicrobial activity of doripenem, a new carbapenem
Ge, YG
Wikler, MA
Sahm, DF
Blosser-Middleton, RS
Karlowsky, JA
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) : 1384 - 1396
[3] MICROBIOLOGY OF AIRWAY DISEASE IN PATIENTS WITH CYSTIC-FIBROSIS
GILLIGAN, PH
[J]. CLINICAL MICROBIOLOGY REVIEWS, 1991, 4 (01) : 35 - 51
[4] LiPuma J J, 1998, Curr Opin Pulm Med, V4, P337, DOI 10.1097/00063198-199811000-00005
[5] Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases
Mushtaq, S
Ge, YG
Livermore, DM
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) : 1313 - 1319
[6] *NAT COMM CLIN LAB, 2002, M100S12 NCCLS, P43
[7] *NAT COMM CLIN LAB, 2004, M100S14 NCCLS, V24, P36
[8] Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation
Saiman, L
Mehar, F
Niu, WW
Neu, HC
Shaw, KJ
Miller, G
Prince, A
[J]. CLINICAL INFECTIOUS DISEASES, 1996, 23 (03) : 532 - 537
[9] Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient-transmission
Saiman, L
Siegel, J
[J]. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2003, 24 (05) : S6 - S52
[10] In vitro and in vivo antibacterial activities of S-4661, a new carbapenem
Tsuji, M
Ishii, Y
Ohno, A
Miyazaki, S
Yamaguchi, K
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (01) : 94 - 99

← 1 2 →